Journal Mobile Options
Table of Contents
Vol. 27, Suppl. 1, 2009
Issue release date: March 2010
Dig Dis 2009;27(suppl 1):55–67
(DOI:10.1159/000268122)

Experimental Models of Stress and Pain: Do They Help to Develop New Therapies?

Bradesi S. · Mayer E.A.
UCLA Center for Neurobiology of Stress, Departments of Medicine, Physiology and Psychiatry, David Geffen School of Medicine at UCLA, and VA Greater Los Angeles Healthcare System, Los Angeles, Calif., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

The majority of functional gastrointestinal disorders are characterised by recurrent abdominal pain, with stress playing an important role in first onset and exacerbation of existing symptoms. These disorders are currently defined by symptom criteria, while their pathophysiology remains controversial and incompletely understood. Modeling these disorders in humans and animals has been difficult. While some of the models have adequate face and construct validity, the predictive validity of most of the models has been disappointing, which has put into question the traditional modeling approach. Similar problems have been encountered in drug development for pain and psychiatric disorders. New approaches have been proposed in the form of reverse translation, which include better characterisation of biological intermediate phenotypes in human disease which can be modeled in humans and in animals. Continuation of the current approach focusing on complex clinical phenotypes is likely to be ineffective for the development of novel and effect treatments.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Mogil JS: Animal models of pain: progress and challenges. Nat Rev Neurosci 2009;10:283–294.
  2. Mayer EA, Bushnell C: Synthesis; in Mayer EA, Bushnell C (eds): Functional Pain Syndromes: Presentation and Pathophysiology. Seattle, IASP Press, 2009.
  3. Markou A, Chiamulera C, Geyer MA, et al: Removing obstacles in neuroscience drug discovery: the future path for animal models. Neuropsychopharmacology 2009;34:74–89.
  4. Collins SM, Barbara G, Vallance B: Stress, inflammation and the irritable bowel syndrome. Can J Gastroenterol 1999;13:47A–49A.

    External Resources

  5. Barreau F, Ferrier L, Fioramonti J, et al: New insights in the etiology and pathophysiology of irritable bowel syndrome: contribution of neonatal stress models. Pediatr Res 2007;62:240–245.
  6. Longstreth GF, Thompson WG, Chey WD, et al: Functional bowel disorders. Gastroenterology 2006;130:1480–1491, erratum in: Gastroenterology 2006;131:688.
  7. Drossman DA: The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006;130:1377–1390.
  8. Design of Treatment Trials Committee, Irvine EJ, Whitehead WE, et al: Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 2006;130:1538–1551.
  9. Whitehead WE, Delvaux M: Standardization of barostat procedures for testing smooth muscle tone and sensory thresholds in the gastrointestinal tract. The Working Team of Glaxo-Wellcome Research, UK. Dig Dis Sci 1997;42:223–241.
  10. Azpiroz F, Bouin M, Camilleri M, et al: Mechanisms of hypersensitivity in IBS and functional disorders. Neurogastroenterol Motil 2007;19:62–88.
  11. Naliboff BD, Munakata J, Fullerton S, et al: Evidence for two distinct perceptual alterations in irritable bowel syndrome. Gut 1997;41:505–512.
  12. Mertz H, Naliboff B, Munakata J, et al: Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995;109:40–52.
  13. Bouin M, Plourde V, Boivin M, et al: Rectal distension testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds. Gastroenterology 2002;122:1771–1777.
  14. Lembo T, Munakata J, Mertz H, et al: Evidence for the hypersensitivity of lumbar splanchnic afferents in irritable bowel syndrome. Gastroenterology 1994;107:1686–1696.
  15. Whitehead WE, Crowell MD, Davidoff AL, et al: Pain from rectal distension in women with irritable bowel syndrome: relationship to sexual abuse. Dig Dis Sci 1997;42:796–804.
  16. Verne GN, Robinson ME, Price DD: Hypersensitivity to visceral and cutaneous pain in the irritable bowel syndrome. Pain 2001;93:7–14.
  17. Naliboff BD, Berman S, Suyenobu B, et al: Longitudinal change in perceptual and brain activation response to visceral stimuli in irritable bowel syndrome patients. Gastroenterology 2006;131:352–365.
  18. Whitehead WE, Palsson OS: Is rectal pain sensitivity a biological marker for irritable bowel syndrome: psychological influences on pain perception. Gastroenterology 1998;115:1263–1271.
  19. Prior A, Sorial E, Sun WM, et al: Irritable bowel syndrome: differences between patients who show rectal sensitivity and those who do not. Eur J Gastroenterol Hepatol 1993;5:343–349.

    External Resources

  20. Ng C, Malcolm A, Hansen R, et al: Distension technique influences the relationship between colonic and rectal hypersensitivity in irritable bowel syndrome. Neurogastroenterol Motil 2006;18:206–210.
  21. Chang L, Mayer EA, Fitzgerald L, et al: Altered perception of somatic stimuli by IBS patients with and without fibromyalgia (FM). Gastroenterology 1997;112:709.
  22. Accarino AM, Azpiroz F, Malagelada JR: Selective dysfunction of mechanosensitive intestinal afferents in irritable bowel syndrome. Gastroenterology 1995;108:636– 643.
  23. Munakata J, Naliboff B, Harraf F, et al: Repetitive sigmoid stimulation induces rectal hyperalgesia in patients with irritable bowel syndrome. Gastroenterology 1997;112:55–63.
  24. Chang L, Mayer EA, Labus JS, et al: Effect of sex on perception of rectosigmoid stimuli in irritable bowel syndrome. Am J Physiol Regul Integr Comp Physiol 2006;291:R277–R284.
  25. Nozu T, Kudaira M, Kitamori S, et al: Repetitive rectal painful distention induces rectal hypersensitivity in patients with irritable bowel syndrome. J Gastroenterol 2006;41:217–222.
  26. Fukudo S, Kanazawa M, Kano M, et al: Exaggerated motility of the descending colon with repetitive distention of the sigmoid colon in patients with irritable bowel syndrome. J Gastroenterol 2002;37:145–150.
  27. Lembo T, Naliboff BD, Matin K, et al: Irritable bowel syndrome patients show altered sensitivity to exogenous opioids. Pain 2000;87:137–147.
  28. Delvaux M, Louvel D, Lagier E, et al: The kappa agonist fedotozine relieves hypersensitivity to colonic distension in patients with irritable bowel syndrome. Gastroenterology 1999;116:38–45.
  29. Bradette M, Delvaux M, Staumont G, et al: Octreotide increases thresholds of colonic visceral perception in IBS patients without modifying muscle tone. Dig Dis Sci 1994;39:1171–1178.
  30. Coffin B, Farmachidi JP, Rueegg P, et al: Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects. Aliment Pharmacol Ther 2003;17:577–585.
  31. Kuiken SD, Tytgat GN, Boeckxstaens GE: Review article: drugs interfering with visceral sensitivity for the treatment of functional gastrointestinal disorders – the clinical evidence. Aliment Pharmacol Ther 2005;21:633–651.
  32. Dapoigny M, Abitbol JL, Fraitag B: Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome: a multicenter dose-response study. Dig Dis Sci 1995;40:2244–2249.
  33. Delvaux M, Beck A, Jacob J, et al: Effect of asimadoline, a kappa opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2004;20:237–246.
  34. Klooker TK, Beaumont H, Kuiken SD, et al: Octreotide as potential treatment for patients with non-constipated irritable bowel syndrome. Gastroenterology 2005;128: A-93–A-94.
  35. Delvaux M, Louvel D, Mamet JP, et al: Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1998;12:849–855.
  36. Thumshirn M, Coulie B, Camilleri M, et al: Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2000;14:869–878.
  37. Zighelboim J, Talley NJ, Phillips SF, et al: Visceral perception in irritable bowel syndrome. Dig Dis Sci 1995;40:819–827.
  38. Goldberg PA, Kamm MA, Setti-Carraro P, et al: Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (ondansetron). Digestion 1996;57:478–483.
  39. Hammer J, Phillips SF, Talley NJ, et al: Effect of a 5-HT3-antagonist (ondansetron) on rectal sensitivity and compliance in health and the irritable bowel syndrome. Aliment Pharmacol Ther 1993;7:543–551.
  40. Zerbib F, Bruley des Varannes S, Oriola RC, et al: Alosetron does not affect the visceral perception of gastric distension in healthy subjects. Aliment Pharmacol Ther 1994;8:403–407.
  41. Camilleri M, Mayer EA, Drossman DA, et al: Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT 3 receptor antagonist. Aliment Pharmacol Ther 1999;13:1149–1159.
  42. Naliboff BD, Chang L, Crowell MD, et al: Tegaserod increases sigmoid accommodation in female irritable bowel syndrome (IBS) patients. Gastroenterology 2004;126:A-101.

    External Resources

  43. Mayer EA, Tillisch K, Bradesi S: Review article: modulation of the brain-gut axis as a therapeutic approach in gastrointestinal disease. Aliment Pharmacol Ther 2006;24:919–933.
  44. Cremonini F, Camilleri M, McKinzie S, et al: Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic study. Am J Gastroenterol 2005;100:652–663.
  45. Camilleri M, McKinzie S, Fox J, et al: Renzapride accelerates colonic transit and improves bowel function in constipation-predominant irritable bowel syndrome (C-IBS). Gastroenterology 2004;126:A-642.

    External Resources

  46. Bouchoucha M, Devroede G, Dorval E, et al: Different segmental transit times in patients with irritable bowel syndrome and ‘normal’ colonic transit time: is there a correlation with symptoms? Tech Coloproctol 2006;10:287–296.
  47. Drossman DA, Morris CB, Hu Y, et al: A prospective assessment of bowel habit in irritable bowel syndrome in women: defining an alternator. Gastroenterology 2005;128:580–589.
  48. Spiegel BM, Strickland A, Naliboff BD, Mayer EA, Chang L: Predictors of patient-assessed illness severity in irritable bowel syndrome. Am J Gastroenterol 2008;103:2536– 2543.
  49. Spiegel BM, Gralnek IM, Bolus R, et al: Clinical determinants of health-related quality of life in patients with irritable bowel syndrome. Arch Intern Med 2004;164:1773–1780.
  50. Ness TJ, Gebhart GF: Characterization of neurons responsive to noxious colorectal distension in the T13-L2 spinal cord of the rat. J Neurophysiol 1988;60:1419–1438.
  51. Tammpere A, Brusberg M, Axenborg J, et al: Evaluation of pseudo-affective responses to noxious colorectal distension in rats by manometric recordings. Pain 2005;116:220–226.
  52. Larsson M, Arvidsson S, Ekman C, et al: A model for chronic quantitative studies of colorectal sensitivity using balloon distension in conscious mice – effects of opioid receptor agonists. Neurogastroenterol Motil 2003;15:371–381.
  53. Kamp EH, Jones RC 3rd, Tillman SR, et al: Quantitative assessment and characterization of visceral nociception and hyperalgesia in mice. Am J Physiol Gastrointest Liver Physiol 2003;284:G434–G444.
  54. Arvidsson S, Larsson M, Larsson H, et al: Assessment of visceral pain-related pseudo-affective responses to colorectal distension in mice by intracolonic manometric recordings. J Pain 2006;7:108–118.
  55. Mayer EA, Naliboff BD, Craig AD: Neuroimaging of the brain-gut axis: from basic understanding to treatment of functional GI disorders. Gastroenterology 2006;131:1925–1942.
  56. Su X, Julia V, Gebhart GF: Effects of intracolonic opioid receptor agonists on polymodal pelvic nerve afferent fibers in the rat. J Neurophysiol 2000;83:963–970.
  57. Booth CE, Kirkup AJ, Hicks GA, et al: Somatostatin sst(2) receptor-mediated inhibition of mesenteric afferent nerves of the jejunum in the anesthetized rat. Gastroenterology 2001;121:358–369.
  58. Coutinho SV, Plotsky PM, Sablad M, et al: Neonatal maternal separation alters stress-induced responses to viscerosomatic nociceptive stimuli in rat. Am J Physiol Gastrointest Liver Physiol 2002;282:G307–G316.
  59. Rosztoczy A, Fioramonti J, Jarmay K, et al: Influence of sex and experimental protocol on the effect of maternal deprivation on rectal sensitivity to distension in the adult rat. Neurogastroenterol Motil 2003;15:679–686.
  60. Schwetz I, Bradesi S, McRoberts JA, et al: Delayed stress-induced colonic hypersensitivity in male Wistar rats: role of neurokinin-1 and corticotropin-releasing factor-1 receptors. Am J Physiol Gastrointest Liver Physiol 2004;286:G683–G691.
  61. Bradesi S, Schwetz I, Ennes HS, et al: Repeated exposure to water avoidance stress in rats: a new model for sustained visceral hyperalgesia. Am J Physiol Gastrointest Liver Physiol 2005;289:G42–G53.
  62. Greenwood-Van Meerveld B, Johnson AC, Foreman RD, et al: Spinal cord stimulation attenuates visceromotor reflexes in a rat model of post-inflammatory colonic hypersensitivity. Auton Neurosci 2005;122:69–76.
  63. McLean PG, Picard C, Garcia-Villar R, et al: Role of kinin B1 and B2 receptors and mast cells in post intestinal infection-induced hypersensitivity to distension. Neurogastroenterol Motil 1998;10:499–508.
  64. Barbara G, Vallance BA, Collins SM: Persistent intestinal neuromuscular dysfunction after acute nematode infection in mice. Gastroenterology 1997;113:1224–1232.
  65. Neubert JK, Widmer CG, Malphurs W, et al: Use of a novel thermal operant behavioral assay for characterization of orofacial pain sensitivity. Pain 2005;116:386–395.
  66. Jabakhanji R, Foss JM, Berra HH, et al: Inflammatory and neuropathic pain animals exhibit distinct responses to innocuous thermal and motoric challenges. Mol Pain 2006;2:1.
  67. Baliki M, Calvo O, Chialvo DR, et al: Spared nerve injury rats exhibit thermal hyperalgesia on an automated operant dynamic thermal escape Task. Mol Pain 2005;1:18.
  68. Temple JL, Bradshaw HB, Wood E, et al: Effects of hypogastric neurectomy on escape response to uterine distention in the rat. Pain 1999;suppl 6:S13–S20.
  69. Wang Z, Bradesi S, Maarek JMI, et al: Functional brain activation and visceral pain measurements in response to colorectal distension in unrestrained conscious rats. Gastroenterology 2007;132:A-717.
  70. Holschneider DP, Yang J, Sadler TR, et al: Mapping cerebral blood flow changes during auditory-cued conditioned fear in the nontethered, nonrestrained rat. Neuroimage 2006;29:1344–1358.
  71. Gao J, Wu X, Owyang C, et al: Enhanced responses of the anterior cingulate cortex neurones to colonic distension in viscerally hypersensitive rats. J Physiol 2006;570:169–183.
  72. Li L, Ding J, Ren Z, et al: Expression and colocalization of NADPH-diaphorase and Fos in the subnuclei of the parabrachial nucleus in rats following visceral noxious stimulation. Brain Res 2006;1114:41–52.
  73. Camilleri M, Bueno L, De Ponti F, et al: Pharmacological and pharmacokinetic aspects of functional gastrointestinal disorders. Gastroenterology 2006;130:1421–1434.
  74. Drossman DA, Camilleri M, Mayer EA, et al: AGA technical review on irritable bowel syndrome. Gastroenterology 2002;123:2108–2131.
  75. Labus JS, Mayer EA, Chang L, et al: The central role of gastrointestinal-specific anxiety in irritable bowel syndrome: further validation of the Visceral Sensitivity Index. Psychosom Med 2007;69:89–98.
  76. Mayer EA, Berman S, Suyenobu B, et al: Differences in brain responses to visceral pain between patients with irritable bowel syndrome and ulcerative colitis. Pain 2005;115:398–409.
  77. Schwetz I, McRoberts JA, Coutinho SV, et al: Corticotropin-releasing factor receptor 1 mediates acute and delayed stress-induced visceral hyperalgesia in maternally separated Long Evans rats. Am J Physiol Gastrointest Liver Physiol 2005;289:G704–G712.
  78. Al-Chaer ED, Kawasaki M, Pasricha PJ: A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development. Gastroenterology 2000;119:1276–1285.
  79. Gue M, Bonbonne C, Fioramonti J, et al: Stress-induced enhancement of colitis in rats: CRF and ariginine vasopressin are not involved. Am J Physiol Gastrointest Liver Physiol 1997;272:G84–G91.
  80. Lister RG: Ethologically-based animal models of anxiety disorders. Pharmacol Ther 1990;46:321–340.
  81. Lang PJ, Davis M, Ohman A: Fear and anxiety: animal models and human cognitive psychophysiology. J Affect Disord 2000;61:137–159.
  82. Sanger GJ: Neurokinin NK1 and NK3 receptors as targets for drugs to treat gastrointestinal motility disorders and pain. Br J Pharmacol 2004;141:1303–1312.
  83. Martinez V, Taché Y: CRF1 receptors as a therapeutic target for irritable bowel syndrome. Curr Pharm Des 2006;12:4071–4088.
  84. Sweetser S, Camilleri M, Linker Nord SJ, et al: Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome? Am J Physiol Gastrointest Liver Physiol 2009;296:G1299–G1306.
  85. Dukes GE, Mayer EA, Kelleher DL, et al: A randomised, double blind, placebo (PLA) controlled, crossover study to evaluate the efficacy and safety of the corticotrophin releasing factor 1 (CRF1) receptor antagonist (RA) GW876008 in irritable bowel syndrome (IBS) patients (PTS) (abstract). Neurogastroenterology and Motility Meeting, Chicago, 2009.
  86. Hill R: NK1 (substance P) receptor antagonists – why are they not analgesic in humans? Trends Pharmacol Sci 2000;21:244–246.
  87. Mogil JS, Chanda ML: The case for the inclusion of female subjects in basic science studies of pain. Pain 2005;117:1–5.
  88. Lariviere WR, Chesler EJ, Mogil JS: Transgenic studies of pain and analgesia: mutation or background genotype? J Pharmacol Exp Ther 2001;297:467–473.
  89. Wang Z, Bradesi S, Maarek JM, et al: Regional brain activation in conscious, nonrestrained rats in response to noxious visceral stimulation. Pain 2008;138:233–243.
  90. Tillisch K, Wang Z, Kilpatrick L, et al: Studying the brain-gut axis with pharmacological imaging. Ann NY Acad Sci 2008;1144:256–264.
  91. Mayer EA, Bradesi S: Alosetron and irritable bowel syndrome. Expert Opin Pharmacother 2003;4:2089–2098.
  92. Berman SM, Chang L, Suyenobu B, et al: Condition-specific deactivation of brain regions by 5-HT 3 receptor antagonist alosetron. Gastroenterology 2002;123:969–977.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50